Company news
Aytu BioPharma, Inc. news in 2024
Aytu BioPharma, Inc.'s news releases, calls and decks from 2024, newest first.
To: all current record holders and beneficial owners of common stock of AYTU BioPharma, Inc. (“AYTU” or the “company”) as of October 9, 2024 (the “record date”) (“current AYTU shareholders”) form 8 k
December 4, 2024
Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results
November 12, 2024
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada
October 2, 2024
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada
September 30, 2024
Aytu BioPharma Reports Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results
September 25, 2024
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
August 5, 2024
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
June 17, 2024
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
May 14, 2024
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
April 2, 2024
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
February 13, 2024
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
February 6, 2024